Page 138 - Škrgat, Sabina, ed. 2022. Severe Asthma - Basic and Clinical Views. Koper: University of Primorska Press. Severe Asthma Forum, 1
P. 138
the TENOR study. Chest. 2007 costeroid dependence: results from a
Dec;132(6):1882-9. French early access programme. Eur
severe asthma forum 1: severe asthma - basic and clinical views 43. Tashkin DP, Chipps B, Trudo F, et al. Respir J. 2020 Jun 25;55(6):902345.
Fixed airflow obstruction in asthma: a doi: 10.1183/13993003.02345-2019.
descriptive study of patient profiles and 52. Rabe KR, Parameswaran N, Brusselle
effect on treatment responses. J Asthma. G, et al. Efficacy and safety of dupi-
2014 Aug;51(6):603-9. lumab in glucocorticoid/dependent se-
44. Mannino DM, Gagnon RC, Petty TL, vere asthma. N Engl J Med. 2018 Jun
et al. Obstructive lung disease and low- 28;378(26):2475-85.
lung function in adults in the United 53. Rogliani P, Calzetta L, Matera MG, et
States: data from the National Health al. Severe Asthma and Biological Ther-
and Nutrition Examination Survey, apy: When, Which, and for Whom.
1988-1994. Arch Intern Med. 2000 Jun Pulm Ther. 2020 Jun;6(1):47-66.
12;160(11):1683-9. 54. Vennera MDC, Sabadell C, Picado C.
45. Fitzpatrick AM, Moore WC. Severe Duration of the efficacy of omalizum-
Asthma Phenotypes - How Should ab after treatment discontinuation in
They Guide Evaluation and Treatment? ‘real life’ severe asthma. Thorax. 2018
J Allergy Clin Immunol Pract. 2017 Jul- Aug;73(8):782-4.
Aug;5(4):901-8. 55. Eraso IC, Sangiovanni S, Mora-
46. McGregor MC, Krings JG, Para- les EI, et al. Use of monoclonal an-
meswaran N, et al. Role of biologics in tibodies for allergic bronchopulmo-
asthma. Am J Respir Crit Care Med. nary aspergillosis in patients with asth-
2019 Feb 15;199(4):433-45. ma and cystic fibrosis: literature re-
47. Brusselle G, Michils A, Louis R, et al. view. Ther Adv Respir Dis. 2020
“Real-life” effectiveness of omalizumab Jan-Dec;14:1753466620961648. doi:
in patients with severe persistent aller- 10.1177/1753466620961648.
gic asthma: the PERSIST study. Respir 56. Global Initiative for Asthma. Global
Med. 2009 Nov; 103(11):1633-42. Strategy for Asthma Management and
48. Agache I, Akdis CA, Akdis M, et al. Prevention [Internet]. [place uknkown:]
EAACI Biologicals Guidelines-Recom- Global Initiative for Asthma; c2022.
mendations for severe asthma. Allergy. Available from: https://ginasthma.org.
2021 Jan;76(1):14-44. 57. Ramonell R, Lee F, Swenson C, et al.
49. Kroes JA, Zielhuis SW, van Roon EN, Dupilumab treatment for allergic bron-
et al. Prediction of response to biolog- chopulmonary aspergillosis: a case se-
ical treatment with monoclonal anti- ries. J Allergy Clin Immunol Pract.
bodies in severe asthma. Biochem Phar- 2020 Feb; 8(2):742-3.
macol. 2020 Sep;179:113978. doi: 58. Faverio P, Bonaiti G, Bini F, et al. Me-
10.1016/j.bcp.2020.113978. polizumab as the first targeted treat-
50. Eger K, Kroes JA, Ten Brinke A, et al. ment for eosinophilic granulomatosis
Long-Term Therapy Response to An- with polyangiitis: a review of current
ti-IL-5 Biologics in Severe Asthma-A evidence and potential place in thera-
Real-Life Evaluation. J Allergy Clin py. Ther Clin Risk Manag. 2018 Dec
Immunol Pract. 2021 Mar;9(3):1194- 7;14:2385-96.
200. 59. Menzella F, Galeone C, Ghidoni G, et
51. Taillé C, Chanez P, Devouassoux G, et al. Successful treatment with benral-
al. Mepolizumab in a population with izumab in a patient with eosinophil-
severe eosinophilic asthma and corti- ic granulomatosis with polyangiitis re-
Dec;132(6):1882-9. French early access programme. Eur
severe asthma forum 1: severe asthma - basic and clinical views 43. Tashkin DP, Chipps B, Trudo F, et al. Respir J. 2020 Jun 25;55(6):902345.
Fixed airflow obstruction in asthma: a doi: 10.1183/13993003.02345-2019.
descriptive study of patient profiles and 52. Rabe KR, Parameswaran N, Brusselle
effect on treatment responses. J Asthma. G, et al. Efficacy and safety of dupi-
2014 Aug;51(6):603-9. lumab in glucocorticoid/dependent se-
44. Mannino DM, Gagnon RC, Petty TL, vere asthma. N Engl J Med. 2018 Jun
et al. Obstructive lung disease and low- 28;378(26):2475-85.
lung function in adults in the United 53. Rogliani P, Calzetta L, Matera MG, et
States: data from the National Health al. Severe Asthma and Biological Ther-
and Nutrition Examination Survey, apy: When, Which, and for Whom.
1988-1994. Arch Intern Med. 2000 Jun Pulm Ther. 2020 Jun;6(1):47-66.
12;160(11):1683-9. 54. Vennera MDC, Sabadell C, Picado C.
45. Fitzpatrick AM, Moore WC. Severe Duration of the efficacy of omalizum-
Asthma Phenotypes - How Should ab after treatment discontinuation in
They Guide Evaluation and Treatment? ‘real life’ severe asthma. Thorax. 2018
J Allergy Clin Immunol Pract. 2017 Jul- Aug;73(8):782-4.
Aug;5(4):901-8. 55. Eraso IC, Sangiovanni S, Mora-
46. McGregor MC, Krings JG, Para- les EI, et al. Use of monoclonal an-
meswaran N, et al. Role of biologics in tibodies for allergic bronchopulmo-
asthma. Am J Respir Crit Care Med. nary aspergillosis in patients with asth-
2019 Feb 15;199(4):433-45. ma and cystic fibrosis: literature re-
47. Brusselle G, Michils A, Louis R, et al. view. Ther Adv Respir Dis. 2020
“Real-life” effectiveness of omalizumab Jan-Dec;14:1753466620961648. doi:
in patients with severe persistent aller- 10.1177/1753466620961648.
gic asthma: the PERSIST study. Respir 56. Global Initiative for Asthma. Global
Med. 2009 Nov; 103(11):1633-42. Strategy for Asthma Management and
48. Agache I, Akdis CA, Akdis M, et al. Prevention [Internet]. [place uknkown:]
EAACI Biologicals Guidelines-Recom- Global Initiative for Asthma; c2022.
mendations for severe asthma. Allergy. Available from: https://ginasthma.org.
2021 Jan;76(1):14-44. 57. Ramonell R, Lee F, Swenson C, et al.
49. Kroes JA, Zielhuis SW, van Roon EN, Dupilumab treatment for allergic bron-
et al. Prediction of response to biolog- chopulmonary aspergillosis: a case se-
ical treatment with monoclonal anti- ries. J Allergy Clin Immunol Pract.
bodies in severe asthma. Biochem Phar- 2020 Feb; 8(2):742-3.
macol. 2020 Sep;179:113978. doi: 58. Faverio P, Bonaiti G, Bini F, et al. Me-
10.1016/j.bcp.2020.113978. polizumab as the first targeted treat-
50. Eger K, Kroes JA, Ten Brinke A, et al. ment for eosinophilic granulomatosis
Long-Term Therapy Response to An- with polyangiitis: a review of current
ti-IL-5 Biologics in Severe Asthma-A evidence and potential place in thera-
Real-Life Evaluation. J Allergy Clin py. Ther Clin Risk Manag. 2018 Dec
Immunol Pract. 2021 Mar;9(3):1194- 7;14:2385-96.
200. 59. Menzella F, Galeone C, Ghidoni G, et
51. Taillé C, Chanez P, Devouassoux G, et al. Successful treatment with benral-
al. Mepolizumab in a population with izumab in a patient with eosinophil-
severe eosinophilic asthma and corti- ic granulomatosis with polyangiitis re-
